June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Visit Adherence and Visual Acuity in SCORE2
Author Affiliations & Notes
  • Brian L VanderBeek
    Scheie Eye Institute, Philadelphia, Pennsylvania, United States
    University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Yinxi Yu
    University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Neal Oden
    The Emmes Company LLC, Rockville, Maryland, United States
  • Paul C Van Veldhuisen
    The Emmes Company LLC, Rockville, Maryland, United States
  • Barbara A Blodi
    University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Michael S Ip
    University of California Los Angeles, Los Angeles, California, United States
  • Ingrid U Scott
    The Pennsylvania State University, University Park, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Brian VanderBeek EyePoint Pharmaceuticals, Code C (Consultant/Contractor); Yinxi Yu None; Neal Oden None; Paul Van Veldhuisen None; Barbara Blodi None; Michael Ip Boehringer Ingelheim, Thrombogenics, Quark, Omeros, Allergan, Amgen, Astellas, Alimera, Novartis, Genetech, Clearside, Biogen, Code C (Consultant/Contractor), Novartis, Genetech, Clearside, Biogen, Code R (Recipient); Ingrid Scott None
  • Footnotes
    Support  NEI grants University of Pennsylvania Core Grant for Vision Research (2P30EY001583) and SCORE2 was supported by the National Eye Institute of the National Institutes of Health under Awards Numbered U10EY023533, U10EY023529, and U10EY023521
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2672. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Brian L VanderBeek, Yinxi Yu, Neal Oden, Paul C Van Veldhuisen, Barbara A Blodi, Michael S Ip, Ingrid U Scott; Visit Adherence and Visual Acuity in SCORE2. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2672.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The impact of missed appointments for anti-vascular endothelial growth factor (anti-VEGF) injection treatment for macular edema due to retinal vein occlusion (MERVO) on visual acuity (VA) is unknown. We performed a secondary analysis of Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) data to evaluate the association between patients’ adherence to clinical trial visits and VA in patients with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO).

Methods : The SCORE2 protocol included a visit every 4 weeks (every 28-35 days) during the first year. Visit adherence was measured as: number of missed visits, average (avg days) and longest (max days) visit interval, average (avg missed days) and longest (max missed days) unintended visit interval. Avg and max missed days were categorized as on time (0 days), late (>0-60 days), and very late (>60 days). Primary outcome was change in Early Treatment Diabetic Retinopathy Study (ETDRS) VA between baseline study visit and last attended visit during Year 1, using multivariate linear regression models controlling for baseline VA, baseline central subfield thickness, age, gender, race, ethnicity, study eye disease type, prior anti-VEGF in study eye, disease duration at baseline, history of diabetes, coronary artery disease or hypertension, whether or not patient was re-randomized at Month 6, and total number of injections.

Results : Of the 362 patients enrolled in SCORE2, 358 were included in the study. Only 48 patients missed a visit during the initial year of follow up, and only 12 missed more than 1 visit. After adjustment, for each visit missed, patients lost 3.0 letters (95%CI: -6.2, 0.2) of vision (p=0.07). On average, the 48 patients who missed at least 1 visit lost 9.4 letters (95%CI: -14.4, -4.3, p<0.001) of vision after adjustment. Average days and maximal interval between visit were not associated with changes in VA (p>0.22) for both comparisons). However, when a visit was missed, the average missed days between missed visits and the max missed interval were both associated with loss of VA (both variables: 0 days missed as reference, late [1-60 days] -10.8 letters [95%CI: -16.9, -4.7], very late [>60 days] -7.3 letters [95%CI: -14.5, -0.2]; p=0.003 for both). See Table 1 for additional results.

Conclusions : Visit adherence is associated with VA outcomes during Year 1 in SCORE2 participants.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×